Amlodipine Besylate/Fimasartan Potassium Trihydrate/Rosuvastatin Calcium

苯磺酸氨氯地平/非马沙坦钾三水合物/舒伐他汀钙

Report date: 2026/02/03 10:42:42

Base Information

Drug NameAmlodipine Besylate/Fimasartan Potassium Trihydrate/Rosuvastatin Calcium
Drug Alias Name氨氯地平/非马沙坦钾/瑞舒伐他汀钙Rosuvastatin Calcium/Fimasartan Potassium Trihydrate/Amlodipine BesylateFimasartan Potassium Trihydrate/Rosuvastatin Calcium/Amlodipine Besylate非马沙坦钾/瑞舒伐他汀钙/氨氯地平Amlodipine besilate/Fimasartan Potassium Trihydrate/Rosuvastatin Calcium +[15] 
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsHMG-CoA reductase inhibitorsVoltage-gated calcium channel blockers
TargetsAngiotensin II Receptor Type 1Voltage-gated calcium channelHMG-CoA reductase
Therapy Area/IndicationsHyperlipidemiasDyslipidemiasEssential Hypertension +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes Fimasartan Potassium TrihydrateAmlodipine BesylateRosuvastatin Calcium
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBoryung Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoryung Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsHyperlipidemiasDyslipidemiasEssential Hypertension +[4] 

Other Information

ATC CodeN/A
Related LinksN/A